British pharmaceutical company AstraZeneca is the sponsor of the Oxford University vaccine, while the University of Queensland vaccine is being marketed by Seqirus (CSL).
Plans to distribute the vaccine quickly across the population once successful phase three trials are complete mean the full safety picture will not be known when the first doses are administered.
Tuesday’s federal budget assumed a nation-wide vaccination program would be rolled out next year.
But the government has rejected calls to set up a no-fault vaccine injury compensation scheme, instead opting to pick up the bill for any compensation payout if a member of the public takes legal action against the drug companies.
University of Sydney Associate Professor Nick Wood, a vaccine expert who designs hospital immunisation programs, said Australians who received a COVID-19 vaccine “for the benefit of themselves and the community” deserved the reassurance of a “safety net” through a no-fault scheme in case they experienced a rare adverse reaction.
Grattan Institute health economist Stephen Duckett, a former secretary of the federal health department, agreed that such a scheme was needed, saying there would “inevitably” be some adverse events associated with the vaccines and that some may take years to appear.
No-fault vaccine injury compensation schemes allow people who experience an adverse reaction to access compensation without having to convince a court that the vaccine was the cause of their injury.
Dr Duckett said safety data would continue to be collected after a COVID-19 vaccine was rolled out, giving a clearer picture over time of any adverse events, including by people in vulnerable groups such as diabetics and people with blood pressure conditions.
Professor Wood said community confidence would be vital in ensuring that there was wide enough take-up of the vaccine for it to be effective at preventing COVID-19 from spreading.
“If we get a scare and someone has a reaction, coverage will probably be hard to get up,” he said.
The no-fault schemes operate in Canada, New Zealand, the United States, the United Kingdom, Austria, Denmark, Finland, France, Germany, Hungary, Iceland, Italy, Norway, Russia, Latvia, Slovenia, Sweden, Switzerland, China, Japan, South Korea, Vietnam, Nepal and Thailand.
A spokesman for the federal health department said the government was “committed to providing access to safe and effective COVID-19 vaccines” and had agreed to indemnify the drug companies due to “the need to appropriately share risks associated with achieving early access to a successful vaccine.”
Dana is health and industrial relations reporter for The Sydney Morning Herald and The Age.